DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism.
BACKGROUND
DCB-3503, a tylophorine analog, inhibits the growth of PANC-1 (human pancreatic ductal cancer cell line) and HepG2 (human hepatocellular cancer cell line) tumor xenografts in nude mice. The inhibition of growth leads to cancer cell differentiation instead of cell death. However, the mechanisms of action of tylophorine analogs is unknown.


RESULTS
In this study, we show that DCB-3503 suppresses the expression of pro-oncogenic or pro-survival proteins with short half-lives, including cyclin D1, survivin, beta-catenin, p53, and p21, without decreasing their mRNA levels. Proteasome inhibitor reversed the inhibitory effect of DCB-3503 on expression of these proteins. DCB-3503 inhibited the incorporation of radiolabeled amino acid and thymidine, and to a much lesser degree of uridine, in a panel of cell lines. The mechanism of inhibition of protein synthesis is different from that of cycloheximide (CHX) as assayed in cell culture and HeLa in vitro translation system. Furthermore, in contrast to rapamycin, DCB-3503 does not affect protein synthesis through the mTOR pathway. DCB-3503 treatment shifts the sedimentation profiles of ribosomes and mRNAs towards the polysomal fractions while diminishing monosome abundance, indicative of the inhibition of the elongation step of protein synthesis. Preferential down regulation of several studied proteins under these conditions is likely due to the relative short half-lives of these proteins.


CONCLUSIONS
The inhibitory effect of DCB-3503 on translation is apparently distinct from any of the current anticancer compounds targeting protein synthesis. Translation inhibitors with novel mechanism could complement current chemotherapeutic agents for the treatment of human cancers and suppress the occurrence of drug resistance.
Wang
Ying
Y
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Gao
Wenli
W
Svitkin
Yuri V
YV
Chen
Annie Pei-Chun
AP
Cheng
Yung-Chi
YC
D000470:Alkaloids / Q000737:chemistry*; D000596:Amino Acids / Q000378:metabolism; D015152:Blotting, Northern; D015153:Blotting, Western; D045744:Cell Line, Tumor; D006801:Humans; D007212:Indolizines / Q000737:chemistry* / Q000494:pharmacology*; D010616:Phenanthrenes / Q000737:chemistry* / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D011132:Polyribosomes / Q000187:drug effects / Q000378:metabolism; D014176:Protein Biosynthesis / Q000187:drug effects*; D013936:Thymidine / Q000378:metabolism
D000470:Alkaloids; D000596:Amino Acids; C509364:DCB 3503; D007212:Indolizines; D010616:Phenanthrenes; C004218:tylophorine; D013936:Thymidine